Jiangsu Sihuan Bioengineering Co Ltd

SHE:000518 China Biotechnology
Market Cap
$415.35 Million
CN¥3.05 Billion CNY
Market Cap Rank
#13941 Global
#3625 in China
Share Price
CN¥2.96
Change (1 day)
-1.66%
52-Week Range
CN¥1.81 - CN¥3.01
All Time High
CN¥9.49
Categories
Companies in China Biotechnology
About

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more

Jiangsu Sihuan Bioengineering Co Ltd (000518) - Net Assets

Latest net assets as of September 2025: CN¥385.48 Million CNY

Based on the latest financial reports, Jiangsu Sihuan Bioengineering Co Ltd (000518) has net assets worth CN¥385.48 Million CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥509.14 Million) and total liabilities (CN¥123.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥385.48 Million
% of Total Assets 75.71%
Annual Growth Rate 5.71%
5-Year Change -41.76%
10-Year Change -34.45%
Growth Volatility 76.78

Jiangsu Sihuan Bioengineering Co Ltd - Net Assets Trend (1992–2024)

This chart illustrates how Jiangsu Sihuan Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jiangsu Sihuan Bioengineering Co Ltd (1992–2024)

The table below shows the annual net assets of Jiangsu Sihuan Bioengineering Co Ltd from 1992 to 2024.

Year Net Assets Change
2024-12-31 CN¥398.97 Million -22.19%
2023-12-31 CN¥512.78 Million -13.60%
2022-12-31 CN¥593.50 Million -8.24%
2021-12-31 CN¥646.78 Million -5.59%
2020-12-31 CN¥685.05 Million +3.75%
2019-12-31 CN¥660.31 Million +2.72%
2018-12-31 CN¥642.80 Million -4.85%
2017-12-31 CN¥675.54 Million +10.55%
2016-12-31 CN¥611.10 Million +0.40%
2015-12-31 CN¥608.69 Million -15.65%
2014-12-31 CN¥721.59 Million -1.26%
2013-12-31 CN¥730.78 Million -11.98%
2012-12-31 CN¥830.24 Million -9.34%
2011-12-31 CN¥915.76 Million +4.10%
2010-12-31 CN¥879.72 Million +23.49%
2009-12-31 CN¥712.38 Million +2.82%
2008-12-31 CN¥692.86 Million -16.90%
2007-12-31 CN¥833.76 Million -17.54%
2006-12-31 CN¥1.01 Billion +0.82%
2005-12-31 CN¥1.00 Billion -9.39%
2004-12-31 CN¥1.11 Billion +1.02%
2003-12-31 CN¥1.10 Billion +3.11%
2002-12-31 CN¥1.06 Billion +8.09%
2001-12-31 CN¥983.04 Million +379.92%
2000-12-31 CN¥204.83 Million +30.61%
1999-12-31 CN¥156.83 Million +50.38%
1998-12-31 CN¥104.29 Million -45.09%
1997-12-31 CN¥189.95 Million +5.21%
1996-12-31 CN¥180.55 Million -13.60%
1995-12-31 CN¥208.96 Million -8.59%
1994-12-31 CN¥228.60 Million +8.47%
1993-12-31 CN¥210.74 Million +211.90%
1992-12-31 CN¥67.57 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Sihuan Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 73188567100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥1.03 Billion 276.98%
Other Comprehensive Income CN¥74.04 Million 19.92%
Total Equity CN¥371.71 Million 100.00%

Jiangsu Sihuan Bioengineering Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Sihuan Bioengineering Co Ltd ranked by their market capitalization.

Company Market Cap
G R Infraprojects Limited
NSE:GRINFRA
 		$244.66 Million
Shenzhen Bromake New Material Co. Ltd. A
SHE:301387
 		$244.69 Million
OCEANA GRP RC-001
F:O1F
 		$244.79 Million
Niu Technologies
NASDAQ:NIU
 		$244.81 Million
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
 		$244.58 Million
Mills Estruturas e Serviços de Engenharia S.A
SA:MILS3
 		$244.55 Million
Genfit S.A.
NASDAQ:GNFT
 		$244.43 Million
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
 		$244.43 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Sihuan Bioengineering Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 481,706,954 to 371,713,279, a change of -109,993,675 (-22.8%).
  • Net loss of 109,993,675 reduced equity.
  • Dividend payments of 600,347 reduced retained earnings.
  • Other comprehensive income increased equity by 73,429,517.
  • Other factors decreased equity by 72,829,170.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-109.99 Million -29.59%
Dividends Paid CN¥600.35K -0.16%
Other Comprehensive Income CN¥73.43 Million +19.75%
Other Changes CN¥-72.83 Million -19.59%
Total Change CN¥- -22.83%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Sihuan Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 8.20x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 45.57x to 8.20x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1992-12-31 CN¥0.06 CN¥2.96 x
1993-12-31 CN¥0.20 CN¥2.96 x
1994-12-31 CN¥0.22 CN¥2.96 x
1995-12-31 CN¥0.20 CN¥2.96 x
1996-12-31 CN¥0.17 CN¥2.96 x
1997-12-31 CN¥0.18 CN¥2.96 x
1998-12-31 CN¥0.10 CN¥2.96 x
1999-12-31 CN¥0.15 CN¥2.96 x
2000-12-31 CN¥0.20 CN¥2.96 x
2001-12-31 CN¥0.94 CN¥2.96 x
2002-12-31 CN¥1.02 CN¥2.96 x
2003-12-31 CN¥1.05 CN¥2.96 x
2004-12-31 CN¥1.06 CN¥2.96 x
2005-12-31 CN¥0.96 CN¥2.96 x
2006-12-31 CN¥1.26 CN¥2.96 x
2007-12-31 CN¥0.81 CN¥2.96 x
2008-12-31 CN¥0.67 CN¥2.96 x
2009-12-31 CN¥0.69 CN¥2.96 x
2010-12-31 CN¥0.69 CN¥2.96 x
2011-12-31 CN¥0.69 CN¥2.96 x
2012-12-31 CN¥0.73 CN¥2.96 x
2013-12-31 CN¥0.66 CN¥2.96 x
2014-12-31 CN¥0.66 CN¥2.96 x
2015-12-31 CN¥0.59 CN¥2.96 x
2016-12-31 CN¥0.59 CN¥2.96 x
2017-12-31 CN¥0.61 CN¥2.96 x
2018-12-31 CN¥0.58 CN¥2.96 x
2019-12-31 CN¥0.60 CN¥2.96 x
2020-12-31 CN¥0.62 CN¥2.96 x
2021-12-31 CN¥0.59 CN¥2.96 x
2022-12-31 CN¥0.54 CN¥2.96 x
2023-12-31 CN¥0.47 CN¥2.96 x
2024-12-31 CN¥0.36 CN¥2.96 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Sihuan Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -29.59%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -54.05%
  • • Asset Turnover: 0.36x
  • • Equity Multiplier: 1.53x
  • Recent ROE (-29.59%) is below the historical average (-2.25%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1992 9.52% 8.74% 0.58x 1.88x CN¥-322.59K
1993 9.80% 32.76% 0.24x 1.22x CN¥-414.92K
1994 8.12% 22.45% 0.29x 1.25x CN¥-4.26 Million
1995 -6.84% -24.16% 0.23x 1.25x CN¥-35.19 Million
1996 -15.99% -34.27% 0.30x 1.53x CN¥-46.53 Million
1997 3.12% 2.80% 0.69x 1.61x CN¥-12.79 Million
1998 -29.96% -6152.86% 0.00x 1.73x CN¥-41.67 Million
1999 24.69% 36.79% 0.49x 1.38x CN¥23.04 Million
2000 25.88% 28.31% 0.68x 1.34x CN¥32.53 Million
2001 7.79% 20.83% 0.34x 1.10x CN¥-21.62 Million
2002 8.09% 18.23% 0.41x 1.08x CN¥-20.21 Million
2003 6.32% 18.36% 0.31x 1.13x CN¥-40.24 Million
2004 1.02% 3.60% 0.22x 1.26x CN¥-99.11 Million
2005 -10.36% -50.33% 0.16x 1.30x CN¥-203.52 Million
2006 0.71% 2.55% 0.23x 1.22x CN¥-93.34 Million
2007 -21.33% -62.87% 0.32x 1.07x CN¥-259.73 Million
2008 -20.30% -77.96% 0.23x 1.13x CN¥-208.78 Million
2009 3.28% 12.03% 0.26x 1.06x CN¥-47.90 Million
2010 1.07% 3.67% 0.22x 1.34x CN¥-63.99 Million
2011 -0.84% -2.44% 0.25x 1.37x CN¥-77.01 Million
2012 1.35% 3.84% 0.29x 1.22x CN¥-64.52 Million
2013 -10.47% -33.88% 0.25x 1.22x CN¥-138.22 Million
2014 0.87% 2.47% 0.29x 1.20x CN¥-62.15 Million
2015 -12.27% -31.30% 0.29x 1.38x CN¥-135.11 Million
2016 0.73% 1.37% 0.32x 1.66x CN¥-56.64 Million
2017 1.16% 2.11% 0.37x 1.48x CN¥-55.58 Million
2018 -4.91% -7.44% 0.43x 1.55x CN¥-89.36 Million
2019 2.34% 3.43% 0.46x 1.49x CN¥-47.02 Million
2020 4.26% 5.40% 0.61x 1.29x CN¥-36.79 Million
2021 -6.32% -10.90% 0.44x 1.32x CN¥-98.87 Million
2022 -9.56% -19.72% 0.37x 1.32x CN¥-109.01 Million
2023 -15.63% -31.97% 0.36x 1.37x CN¥-123.44 Million
2024 -29.59% -54.05% 0.36x 1.53x CN¥-147.17 Million

Industry Comparison

This section compares Jiangsu Sihuan Bioengineering Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,087,811,184
  • Average return on equity (ROE) among peers: 16.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangsu Sihuan Bioengineering Co Ltd (000518) CN¥385.48 Million 9.52% 0.32x $244.62 Million
Shenzhen CAU Technology Co Ltd (000004) $124.02 Million 4.50% 1.13x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $525.49 Million 14.76% 1.41x $1.02 Billion
Nanhua Bio Medicine Co Ltd (000504) $174.34 Million 36.11% 1.61x $288.51 Million
Chengzhi Shareholding Co Ltd (000990) $1.69 Billion 3.06% 0.97x $850.04 Million
Hualan Biological EngineeringInc (002007) $1.86 Billion 32.78% 0.08x $2.00 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.09 Billion 4.42% 0.71x $784.18 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $831.21 Million 22.32% 0.12x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $2.04 Billion 5.44% 0.31x $398.99 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $456.61 Million 23.20% 0.29x $347.95 Million